LeMaitre Vascular (NASDAQ: LMAT) director reports new equity award grants

Rhea-AI Filing Summary

LeMaitre Vascular reported that one of its directors received new equity awards. On 12/10/2025 the director was granted 533 restricted stock units of common stock at a price of $0 and 3,431 stock options with an exercise price of $83.66 per share.

The restricted stock units vest 33 1/3% on 12/1/2026, with the rest vesting in equal annual installments over the following two years. The options vest over three years at 33 1/3% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the remaining two years, and expire on 12/10/2030. After this grant, the director beneficially owns 3,455 common shares directly, 181 shares indirectly through a spouse, and 3,431 options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roush John A

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, 63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		A		533(1)	A	$0	3,455	D
Common Stock								181	I	Indirect through spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$83.66	12/10/2025		A		3,431		12/01/2025(2)	12/10/2030	Common Stock	3,431	$0	3,431	D

Explanation of Responses:

1. Represents a restricted stock unit award that vests on a time-based schedule as follows: 33 1/3% of the award vests on 12/1/2026, with the balance vesting in equal annual installments over the remaining two years.

2. This option is exercisable and vests over a three-year period at a rate of 33 1/3% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining two years.

	/s/ Laurie A. Churchill, Attorney-in-fact	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did LeMaitre Vascular (LMAT) report in this Form 4?

The filing shows that a LeMaitre Vascular director was granted 533 restricted stock units of common stock at $0 and 3,431 stock options with an exercise price of $83.66 per share on 12/10/2025.

How many LeMaitre Vascular shares and options does the director hold after the transaction?

Following the reported grants, the director beneficially owns 3,455 shares of LeMaitre Vascular common stock directly, 181 shares indirectly through a spouse, and 3,431 stock options.

What are the vesting terms of the 533 restricted stock units granted by LMAT?

The 533 restricted stock units vest on a time-based schedule: 33 1/3% vests on 12/1/2026, with the remaining units vesting in equal annual installments over the next two years.

What are the key terms of the 3,431 LeMaitre Vascular stock options granted?

The director received 3,431 stock options with an exercise price of $83.66 per share. These options vest over three years at 33 1/3% on the first anniversary of 12/01/2025, with the remainder vesting in equal annual installments over the next two years, and they expire on 12/10/2030.

What is the reporting person’s relationship to LeMaitre Vascular in this filing?

The reporting person is identified as a director of LeMaitre Vascular Inc. on the Form 4.

Is this LMAT Form 4 filed by one reporting person or multiple persons?

The document indicates that the Form 4 is filed by one reporting person, not by a group.